EGFR and colorectal carcinoma: The irrelevance of EGFR status in primary and metastatic CRC can explain to some extent the fact that some CRC patients cannot have a good prognosis after EGFR-targeted monoclonal antibodies, besides through underlying mechanisms the metastatic CRC may alter its biophenotype such as EGFR status to survive from immune elimination and chemotherapeutants.